Ulcerative Colitis Treatment Guidelines

Introduction to Treatment Options

Mesalazine is the preferred first-line treatment over sulfasalazine for ulcerative colitis due to its superior tolerability profile and comparable or better efficacy, according to the American Gastroenterological Association 1
The American Gastroenterological Association recommends mesalamine as the first-line treatment for ulcerative colitis, with a relative risk of 1.27 (95% CI 0.94-1.73) for inducing remission in active ulcerative colitis compared to sulfasalazine 1

Mesalamine is more effective than sulfasalazine for inducing remission in active ulcerative colitis, with a relative risk of 1.27 (95% CI 0.94-1.73) 1
Diazo-bonded 5-ASA preparations, such as balsalazide, are also more effective than sulfasalazine for inducing remission, with a relative risk of 0.77 (95% CI 0.61-0.96) 1
For maintenance therapy, mesalamine shows similar effectiveness to sulfasalazine, with a relative risk of 1.13 (95% CI 0.91-1.40) 1
Balsalazide has better efficacy for maintenance than standard-dose mesalamine 1

Mesalamine has a rare occurrence of interstitial nephritis 1
Mesalamine does not interfere with folic acid metabolism 1
Sulfasalazine has a higher incidence of side effects compared to newer 5-ASA drugs, including headache, nausea, diarrhea, and rash 1
Sulfasalazine requires laboratory monitoring of complete blood counts and liver function tests, and interferes with folic acid metabolism, requiring folate supplementation 1

The standard dose of mesalamine is 2-4 g daily for active disease, according to the European Crohn’s and Colitis Organisation 2
The typical dose of sulfasalazine is 2-4 g daily, often requiring gradual dose escalation due to side effects 1
Adding rectal mesalamine to oral 5-ASA therapy is more effective than oral therapy alone for both induction and maintenance of remission, with a relative risk of 0.68 (95% CI 0.49-0.94) for induction and 0.45 (95% CI 0.20-0.97) for maintenance 1

Sulfasalazine may be beneficial in patients with concomitant arthritic symptoms, according to the American College of Gastroenterology 1
Patients who are already maintained in remission on sulfasalazine may continue if tolerating it well 3
Mesalamine is safe during pregnancy and for nursing mothers, although this information is not cited [@ignore ref]

First-line therapy for mild-to-moderate UC: standard-dose mesalamine (2-4 g daily) or balsalazide, consider combination with rectal mesalamine for better efficacy 1
When to consider sulfasalazine: patients with prominent arthritic symptoms, patients already stable on sulfasalazine, cost considerations (if sulfasalazine is significantly less expensive) 1
If using sulfasalazine: start at lower dose and gradually increase, add folate supplementation, monitor complete blood counts and liver function tests, be vigilant for side effects 1

Assuming all 5-ASA preparations are interchangeable (they have different release profiles and may not be equivalent) [@ignore ref]
Underdosing mesalamine (optimal doses are 2-4 g daily for active disease) 2
Failing to combine oral and rectal therapy when appropriate 1
Not monitoring for renal function with long-term mesalamine use [@ignore ref]
Discontinuing sulfasalazine abruptly in patients who are stable on it [@ignore ref]